Latest revenue
$0
as of 2025-09-30
Latest net income
$-34.4M
as of 2025-09-30
Net margin
—
as of 2025-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AMLX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.48B
- Enterprise value
- $1.25B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 5.42×
- Dividend yield
- 0.0%
- 52-wk high
- $18.61
- 52-wk low
- $4.80
- Beta
- —
- Shares out
- 111.2M
5-year trend
What this company does
Item 1. Business. Overview Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a commercial-stage biotechnology company with a mission to end the suffering caused by neurodegenerative diseases. We have been working in amyotrophic lateral sclerosis, or ALS, and neurodegenerative diseases for over a decade and have been making significant progress in transforming the treatment of these diseases. Since our founding in 2013, we have transformed from a research-stage company focused on addressing the needs of patients suffering from neurodegenerative diseases to a commercial enterprise with development programs across several indications. Our first commercial product,…
AI summary unavailable — showing raw filing excerpt
Generated from AMLX's filing dated 2024-02-22
Key risks
Item 1A. Risk Factors. Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report and in other documents that we file with the SEC, in evaluating our business and our prospects. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks that we face. New risk factors can emerge from time to time, and it is not possible to predict the impact that…
AI summary unavailable — showing raw filing excerpt
Generated from AMLX's filing dated 2024-02-22
Profitability
Operating margin
-360.2%
3635.1%Net margin
-345.4%
2769.1%Return on equity
-87.8%
52.0%Return on assets
-43.5%
72.1%Leverage
Debt / equity
1.02×
481.5%Debt / assets
50.5%
238.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-41.3M | -15.0% | — |
Q4 2025 2025-12-31 | $0 | +100.0% | $-33.0M | +12.1% | — |
Q3 2025 2025-09-30 | $0 | -100.0% | $-34.4M | +52.7% | — |
Q2 2025 2025-06-30 | $0 | +100.0% | $-41.4M | +43.0% | — |
Q1 2025 2025-03-31 | $0 | -100.0% | $-35.9M | +69.8% | — |
Q4 2024 2024-12-31 | $-665.0K | — | $-37.5M | — | — |
Q3 2024 2024-09-30 | $416.0K | -99.6% | $-72.7M | -448.0% | -17476.9% |
Q2 2024 2024-06-30 | $-1.0M | -101.0% | $-72.7M | -429.3% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AMLX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$152.2K
Insider selling
$7.4M
Net activity
−$7.2M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AMLX
Institutional value
$329.0M
Total shares held
24.0M
Distinct holders
86
-92 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.8M | $122.7M | -225.6K (-2.5%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 4.1M | $57.6M | — | New |
| 3 | FRANKLIN RESOURCES INC | 2.3M | $31.4M | +1.1M (+88.4%) | Added |
| 4 | DEUTSCHE BANK AG\ | 1.3M | $17.6M | -65.5K (-4.9%) | Trimmed |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 944.8K | $13.1M | — | New |
| 6 | DIMENSIONAL FUND ADVISORS LP | 903.2K | $12.5M | +131.9K (+17.1%) | Added |
| 7 | Connor, Clark & Lunn Investment Management Ltd. | 868.3K | $12.1M | -135.7K (-13.5%) | Trimmed |
| 8 | JUPITER ASSET MANAGEMENT LTD | 592.7K | $8.2M | +577.1K (+3705.4%) | Added |
| 9 | VANGUARD FIDUCIARY TRUST CO | 586.2K | $8.1M | — | New |
| 10 | FEDERATED HERMES, INC. | 363.5K | $5.1M | -93.9K (-20.5%) | Trimmed |
| 11 | UBS Group AG | 324.3K | $4.5M | -219.0K (-40.3%) | Trimmed |
| 12 | Nuveen, LLC | 264.9K | $3.7M | -19.1K (-6.7%) | Trimmed |
| 13 | Bank of New York Mellon Corp | 251.1K | $3.5M | +33.8K (+15.5%) | Added |
| 14 | Aldebaran Capital, LLC | 197.9K | $2.8M | -616 (-0.3%) | Trimmed |
| 15 | Invesco Ltd. | 171.6K | $2.4M | -4.3K (-2.4%) | Trimmed |
| 16 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 157.1K | $2.2M | +58.3K (+58.9%) | Added |
| 17 | JPMORGAN CHASE & CO | 159.7K | $2.0M | +93.1K (+139.9%) | Added |
| 18 | Swiss National Bank | 130.3K | $1.8M | -31.4K (-19.4%) | Trimmed |
| 19 | Walleye Capital LLC | 123.4K | $1.7M | +117.7K (+2050.2%) | Added |
| 20 | RHUMBLINE ADVISERS | 108.5K | $1.5M | +9.2K (+9.3%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AMLX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.